National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ledipasvir/sofosbuvir (Harvoni®) is indicated for the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4)  in adults.

 Rapid Review

Commenced Completed Outcome
14/11/2014 18/12/2014 Full Pharmacoeconomic Evaluation Recommended.

 

Commenced Completed Outcome
18/03/2015 20/11/2015 Reimbursement Recommended for Genotype 1 and 4.

Summary